Business Wire

TEAMLAB

8.8.2019 12:48:06 CEST | Business Wire | Press release

Share
teamLab Borderless Becomes the Most Visited Single-Artist Museum in the World.

This summer marks the one-year anniversaries for art collective teamLab’s two museums in Tokyo: MORI Building DIGITAL ART MUSEUM: teamLab Borderless (Odaiba, Tokyo; hereafter teamLab Borderless) and teamLab Planets TOKYO (Toyosu, Tokyo; hereafter teamLab Planets). In the one year since their openings, teamLab Borderless and teamLab Planets have seen a combined 3.5 million visitors. teamLab Borderless alone welcomed 2.3 million visitors within one year of opening, exceeding the number of attendees at the Van Gogh Museum in the Netherlands and setting a record number of visitors at a single-artist museum in one year. These visitors came from over 160 countries and regions around the world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190808005373/en/

teamLab Borderless and teamLab Planets are two museums dedicated solely to art by teamLab. teamLab Borderless is a world of ever-changing artworks without boundaries, a “museum without a map.” One year since its opening in June, 2018, the museum has seen approximately 2.3 million visitors from over 160 countries and regions worldwide. teamLab Planets is “a museum where you move through water.” Guests walk barefoot in the space and physically immerse their entire bodies in massive artworks. One year since its opening in July, 2018, the museum has welcomed over 1.25 million visitors from 106 countries and regions around the world.

When compared to the world’s three most-visited single-artist museums of 2018, both teamLab Borderless and teamLab Planets welcomed more visitors than the Picasso Museum in Barcelona, Spain (948,483 visitors), and the Dalí Theatre-Museum in Figueres, Spain (1,105,169 visitors). The number of museum attendees at teamLab Borderless exceeds even those of the Van Gogh Museum in Amsterdam, Netherlands (2,161,160 visitors), making it the world’s most-visited museum dedicated to a single artist. (*1).

  • teamLab Borderless (Odaiba, Tokyo)

Of the 2.3 million visitors to teamLab Borderless, approximately 50% come from overseas (*2), with most coming from the USA, followed by Australia, China, Thailand, Canada, and the UK, making it a museum that attracts not only visitors from neighboring countries, but those from far more distant regions as well. In addition, according to a survey conducted by the museum, it appears that about 50% of the guests from overseas visited Tokyo in order to visit the museum (*3).

  • teamLab Planets (Toyosu, Tokyo)

Of the 1.25 million visitors to teamLab Planets, approximately 30% come from overseas (*4), with the majority coming from the USA, followed by Hong Kong, Taiwan, the UK, and Australia.

-----------------------
*1 ”THE ART NEWSPAPER SPECIAL REPORT Art’s Most Popular: Exhibition and museum visitor figures 2018” The Art Newspaper. Number 311, April, 2019.
*2 teamLab Borderless Official Website, Ticket Purchasing Data (data obtained Feb 16 - June 7, 2019)
*3 teamLab Borderless Visitor Survey (conducted Oct 25 - Nov 2, 2018), 1,237 respondents
*4 teamLab Planets Official Website, Ticket Purchasing Data (data obtained March 1 - June 30, 2019)

About teamLab

teamLab (f. 2001) is an art collective, interdisciplinary group of ultratechnologists whose collaborative practice seeks to navigate the confluence of art, science, technology, design and the natural world. teamLab aims to explore a new relationship between humans and nature, and between oneself and the world through art. Click here for full bio.
teamLab is represented by Pace Gallery .

Press Kit

teamLab Borderless
https://goo.gl/MpzVss
For tickets and more information, please visit borderless.teamlab.art , and follow Instagram .

teamLab Planets
https://goo.gl/tQXMLm
For tickets and more information, please visit planets.teamlab.art , and follow Instagram .

Link:

ClickThru

Social Media:

https://www.facebook.com/teamLab.inc

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye